How do you want your Altace be delivered? Choose here!

BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) today reported that the results of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication study (”DREAM”) were presented at the European Association for the Study of Diabetes (”EASD”) meeting in Copenhagen, Denmark, …

The ACE inhibitor ramipril appears to reduce the risk of developing diabetes among high-risk patients who take it to prevent myocardial infarction, stroke, and diabetic nephropathy, reported Salim Yusuf, D.Phil., and associates in the Heart Outcomes Prevention Evaluation trial.
The HOPE trial involved more than 10,000 subjects treated at 267 hospitals around the world between 1994 and 1999. A subgroup of 5,887 patients who were at risk for diabetes but did n…

Apr 10, 2002 (Pharmacy News

Related Results

RAMIPRIL.Sandoz launches ramiprilCutaneous vasculitis secondary to ramiprilRamipril cuts diabetes riskRamipril-associated hepatotoxicity

ABIX via COMTEX) -…

This study is currently recruiting patients. Verified and sponsored by Sanofi-Aventis. The present study is designed to evaluate the hypothesis that the Angiotensin Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with rheumato…

High blood pressure (also called hypertension) is a life-threatening condition that affects 1 in every 4 Americans over age 18. Anyone can get it, and as you get older, the odds of your developing it increase, especially if you are overweight …

BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues were $492 million during the third quarter ended September 30, 2006, compared to $518 million in the third quarter of 2005. Including special items, net earnings equaled $90 million and diluted earnings per share equaled $0.37 during the third quarter ended September 30, 2006, compared to net income of $122 million and diluted earnings per share of $0.50 in the sa…

CHICAGO — Zacks Equity Research highlights 51job (Nasdaq: JOBS) as the Bull of the Day and Hewitt Associates (NYSE: HEW) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on King Pharmaceuticals (NYSE: KG) and Pride International (NYSE: …

DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c32022) has announced the addition of Barriers to Effective Management of Metabolic Syndrome to their offering.
Business Implications
–Sedentary lifestyles and a steady increase in obesity have contributed to rapid growth in the prevalence of metabolic syndrome in many developed nations.We estimate that, in 2003, almost 123 million people had metabolic syndrome in …

In the Heart Outcomes Prevention Evaluation (HOPE) study, 9,541 patients with cardiovascular disease or diabetes, plus one other cardiovascular risk factor, were randomly assigned to receive, in double-blind fashion, 400 IU/day of vitamin E (RRR-alpha-tocopheryl acetate) or placebo, and either an angiotensin-converting-enzyme inhibitor (ramipril) o…

Oct. 19, 2004 — About a quarter of deaths among women with heart failure can be attributed to kidney problems, new research shows.
And taking a widely available medication may improve outcomes, write lead researcher Kirsten Bibbins-Domingo, PhD, MD, with San Francisco General Hos…